Mayukh Sukhatme - 30 Mar 2026 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
President & CIO, Director
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme
Issuer symbol
ROIV
Transactions as of
30 Mar 2026
Net transactions value
$0
Form type
4
Filing time
01 Apr 2026, 19:19:14 UTC
Previous filing
11 Feb 2026
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Mayukh Sukhatme filed Form 4 for Roivant Sciences Ltd. (ROIV) on 01 Apr 2026."

Quick Takeaways

  • This page summarizes Mayukh Sukhatme's Form 4 filing for Roivant Sciences Ltd. (ROIV).
  • 4 reported transactions and 1 derivative row are listed below.
  • Filing timestamp: 01 Apr 2026, 19:19.

What Changed

  • Previous filing in this sequence was filed on 11 Feb 2026.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sukhatme Mayukh President & CIO, Director C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme 01 Apr 2026 0001750050

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Options Exercise +58,391 +0.31% 18,894,938 30 Mar 2026 Direct F1, F2
transaction ROIV Common Shares Tax liability -29,809 -0.16% $26.41* 18,865,129 30 Mar 2026 Direct F3
transaction ROIV Common Shares Tax liability -187,512 -0.99% $27.70* 18,677,617 31 Mar 2026 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ROIV Capped Value Appreciation Rights Options Exercise -1,306,889 -100% $11.50* 0 30 Mar 2026 Common Shares 58,391 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").
F2 On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.
F3 Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such CVARs.
F4 Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
F5 Award of CVARs is fully vested.

Sponsored